SEARCH

SEARCH BY CITATION

References

  • Abe S., Hu W., Ishibashi H., Hasumi K. and Yamaguchi H. (2004) Augmented inhibition of Candida albicans growth by murine neutrophils in the presence of a tryptophan metabolite, picolinic acid. J Infect Chemother 10, 181184.
  • Adam R., Russing D., Adams O., Ailyati A., Sik Kim K., Schroten H. and Daubener W. (2005) Role of human brain microvascular endothelial cells during central nervous system infection. Significance of indoleamine 2,3-dioxygenase in antimicrobial defence and immunoregulation. Thromb. Haemost. 94, 341346.
  • Adams O., Besken K., Oberdorfer C., MacKenzie C. R., Russing D. and Daubener W. (2004) Inhibition of human herpes simplex virus type 2 by interferon gamma and tumor necrosis factor alpha is mediated by indoleamine 2,3-dioxygenase. Microbes Infect 6, 806812.
  • Aggett P. J., Fenwick P. K. and Kirk H. (1989) An in vitro study of the effect of picolinic acid on metal translocation across lipid bilayers. J. Nutr. 119, 14321437.
  • Beninger R. J., Colton A. M., Ingles J. L., Jhamandas K. and Boegman R. J. (1994) Picolinic acid blocks the neurotoxic but not the neuroexcitant properties of quinolinic acid in the rat brain: evidence from turning behaviour and tyrosine hydroxylase immunohistochemistry. Neuroscience 61, 603612.
  • Benveniste O., Vaslin B., Villinger F., Le Grand R., Ansari A. A. and Dormont D. (1996) Cytokine mRNA levels in unmanipulated (ex vivo) and in vitro stimulated monkey PBMCs using a semi-quantitative RT-PCR and high sensitivity fluorescence-based detection strategy. Cytokine 8, 3241.
  • Bosco M. C., Rapisarda A., Massazza S., Melillo G., Young H. and Varesio L. (2000) The tryptophan catabolite picolinic acid selectively induces the chemokines macrophage inflammatory protein-1 alpha and -1 beta in macrophages. J. Immunol. 164, 32833291.
  • Cai S., Sato K., Shimizu T., Yamabe S., Hiraki M., Sano C. and Tomioka H. (2006) Antimicrobial activity of picolinic acid against extracellular and intracellular Mycobacterium avium complex and its combined activity with clarithromycin, rifampicin and fluoroquinolones. J. Antimicrob. Chemother. 57, 8593.
  • Daubener W., Spors B., Hucke C., Adam R., Stins M., Kim K. S. and Schroten H. (2001) Restriction of Toxoplasma gondii growth in human brain microvascular endothelial cells by activation of indoleamine 2,3-dioxygenase. Infect. Immun. 69, 65276531.
  • Dykens J. A., Sullivan S. G. and Stern A. (1987) Oxidative reactivity of the tryptophan metabolites 3-hydroxyanthranilate, cinnabarinate, quinolinate and picolinate. Biochem. Pharmacol. 36, 211217.
  • Fallarino F., Grohmann U., You S., et al. (2006) The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176, 67526761.
  • Feng H. M. and Walker D. H. (2000) Mechanisms of intracellular killing of Rickettsia conorii in infected human endothelial cells, hepatocytes, and macrophages. Infect. Immun. 68, 67296736.
  • Fernandez-Pol J.A., Klos D. J. and Hamilton P. D. (2001) Antiviral, cytotoxic and apoptotic activities of picolinic acid on human immunodeficiency virus-1 and human herpes simplex virus-2 infected cells. Anticancer Res. 21, 37733776.
  • Friberg M., Jennings R., Alsarraj M., Dessureault S., Cantor A., Extermann M., Mellor A. L., Munn D. H. and Antonia S. J. (2002) Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int. J. Cancer 101, 151155.
  • Frumento G., Rotondo R., Tonetti M., Damonte G., Benatti U. and Ferrara G. B. (2002) Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196, 459468.
  • Goldstein L. E., Leopold M. C., Huang X., et al. (2000) 3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. Biochemistry 39, 72667275.
  • Grohmann U., Fallarino F. and Puccetti P. (2003) Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 24, 242248.
  • Guillemin G. J., Kerr S. J., Smythe G. A., Smith D. G., Kapoor V., Armati P. J., Croitoru J. and Brew B. J. (2001) Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J. Neurochem. 78, 842853.
  • Heyes M. P., Brew B. J., Martin A., Price R. W., Salazar A. M., Sidtis J. J., Yergey J. A., Mouradian M. M., Sadler A. E. and Keilp J. (1991) Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann. Neurol. 29, 202209.
  • Heyes M. P., Saito K. and Markey S. P. (1992) Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid. Biochem. J. 283, 633635.
  • Heyes M. P., Jordan E. K., Lee K., Saito K., Frank J. A., Snoy P. J., Markey S. P. and Gravell M. (1992) Relationship of neurologic status in macaques infected with the simian immunodeficiency virus to cerebrospinal fluid quinolinic acid and kynurenic acid. Brain Res. 570, 237250.
  • Hu B., Hissong B. D. and Carlin J. M. (1995) Interleukin-1 enhances indoleamine 2,3-dioxygenase activity by increasing specific mRNA expression in human mononuclear phagocytes. J. Interferon Cytokine Res. 15, 617624.
  • Hunt N. H., Golenser J., Chan-Ling T., Parekh S., Rae C., Potter S., Medana I. M., Miu J. and Ball H. J. (2006) Immunopathogenesis of cerebral malaria. Int. J. Parasitol. 36, 569582.
  • Ishii T., Iwahashi H., Sugata R., Kido R. and Fridovich I. (1990) Superoxide dismutases enhance the rate of autoxidation of 3-hydroxyanthranilic acid. Arch. Biochem. Biophys. 276, 248250.
  • Jhamandas K. H., Boegman R. J., Beninger R. J. and Flesher S. (1998) Role of zinc in blockade of excitotoxic action of quinolinic acid by picolinic acid. Amino Acids 14, 257261.
  • Kalisch B. E., Jhamandas K., Boegman R. J. and Beninger R. J. (1994) Picolinic acid protects against quinolinic acid-induced depletion of NADPH diaphorase containing neurons in the rat striatum. Brain Res. 668, 18.
  • Kerr S. J., Armati P. J. and Brew B. J. (1995) Neurocytotoxity of quinolinic acid in human brain cultures. J. Neurovirol. 1, 375380.
  • Kerr S. J., Armati P. J., Guillemin G. J. and Brew B. J. (1998) Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex. AIDS 12, 355363.
  • Kerr S. J., Armati P. J., Pemberton L. A., Smythe G., Tattam B. and Brew B. J. (1997) Kynurenine pathway inhibition reduces neurotoxicity of HIV-1-infected macrophages. Neurology 49, 16711681.
  • Mellor A. L., Chandler P., Baban B., Hansen A. M., Marshall B., Pihkala J., Waldmann H., Cobbold S., Adams E. and Munn D. H. (2004) Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int. Immunol. 16, 13911401.
  • Moffett J. R. and Namboodiri M. A. (2003) Tryptophan and the immune response. Immunol. Cell Biol. 81, 247265.
    Direct Link:
  • Mukhtar M., Harley S., Chen P., BouHamdan M., Patel C., Acheampong E. and Pomerantz R. J. (2002) Primary isolated human brain microvascular endothelial cells express diverse HIV/SIV-associated chemokine coreceptors and DC-SIGN and L-SIGN. Virology 297, 7888.
  • Munn D. H. and Mellor A. L. (2004) IDO and tolerance to tumors. Trends Mol Med 10, 1518.
  • Munn D. H., Sharma M. D. and Mellor A. L. (2004) Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol. 172, 41004110.
  • Nemeth H., Toldi J. and Vecsei L. (2005) Role of kynurenines in the central and peripheral nervous systems. Curr Neurovasc Res 2, 249260.
  • Nicholls T., Nitsos I., Smythe G. and Walker D. W. (2001) Kynurenine production and catabolism in fetal sheep with embolized or nonembolized placentas. Am. J. Obstet. Gynecol. 185, 988995.
  • Pais T. F. and Appelberg R. (2000) Macrophage control of mycobacterial growth induced by picolinic acid is dependent on host cell apoptosis. J. Immunol. 164, 389397.
  • Poljak A., Grant R., Austin C.J., Jamie J. F., Willows R. D., Takikawa O., Littlejohn T. K., Truscott R. J., Walker M. J., Sachdev P. and Smythe G. A. (2006) Inhibition of indoleamine 2,3 dioxygenase activity by H2O2. Arch. Biochem. Biophys. 450, 919.
  • Saito K., Markey S. P. and Heyes M. P. (1992) Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse. Neuroscience 51, 2539.
  • Schlingemann R. O., Rietveld F. J., De Waal R. M., Ferrone S. and Ruiter D. J. (1990) Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am. J. Pathol. 136, 1393405.
  • Schroten H., Spors B., Hucke C., Stins M., Kim K. S., Adam R. and Daubener W. (2001) Potential role of human brain microvascular endothelial cells in the pathogenesis of brain abscess: inhibition of Staphylococcus aureus by activation of indoleamine 2,3-dioxygenase. Neuropediatrics 32, 206210.
  • Shimizu T. and Tomioka H. (2006) Activity of picolinic acid in combination with the antiprotozoal drug quinacrine against Mycobacterium avium complex. Antimicrob. Agents Chemother. 50, 31863188.
  • Smith D. G., Guillemin G. J., Pemberton L., Kerr S., Nath A., Smythe G. A. and Brew B. J. (2001) Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat. J. Neurovirol. 7, 5660.
  • Smythe G. A., Braga O., Brew B. J., Grant R. S., Guillemin G. J., Kerr S. J. and Walker D. W. (2002) Concurrent quantification of quinolinic, picolinic, and nicotinic acids using electron-capture negative-ion gas chromatography-mass spectrometry. Anal. Biochem. 301, 2126.
  • Stazka J., Luchowski P., Wielosz M., Kleinrok Z. and Urbanska E. M. (2002) Endothelium-dependent production and liberation of kynurenic acid by rat aortic rings exposed to L-kynurenine. Eur. J. Pharmacol. 448, 133137.
  • Stone T. W. (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45, 309379.
  • Stone T. W. (2000) Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol Sci 21, 149154.
  • Stone T. W. and Addae J. I. (2002) The pharmacological manipulation of glutamate receptors and neuroprotection. Eur. J. Pharmacol. 447, 285296.
  • Stone T. W. and Darlington L. G. (2002) Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 1, 609620.
  • Takikawa O., Kuroiwa T., Yamazaki F. and Kido R. (1988) Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J. Biol. Chem. 263, 20412048.
  • Takikawa O., Tagawa Y., Iwakura Y., Yoshida R. and Truscott R. J. (1999) Interferon-gamma-dependent/independent expression of indoleamine 2,3-dioxygenase. Studies with interferon-gamma-knockout mice. Adv. Exp. Med. Biol. 467, 553557.
  • Wacker H. H., Hansmann M. L., Lumbeck H., Radzun H. J. and Parwaresch M. R. (1990) A new pan-macrophage antibody Ki-M1P stains plasmacytoid cells in paraffin sections of lymph nodes. Verh Dtsch Ges Pathol 74, 159164.
  • Wejksza K., Rzeski W., Parada-Turska J., Zdzisinska B., Rejdak R., Kocki T., Okuno E., Kandefer-Szerszen M., Zrenner E. and Turski W. A. (2004) Kynurenic acid production in cultured bovine aortic endothelial cells. Homocysteine is a potent inhibitor. Naunyn Schmiedebergs Arch Pharmacol 369, 300304.